維力醫療(603309.SH):全資子公司通過高新技術企業認定
格隆匯1月4日丨維力醫療(603309.SH)公佈,根據全國高新技術企業認定管理工作領導小組辦公室2021年12月31日下發的《關於對海南省2021年認定的第二批高新技術企業進行備案的公吿》,公司全資子公司海南維力醫療科技開發有限公司(以下簡稱“海南維力”)順利通過海南省2021年第二批高新技術企業的備案。
根據《中華人民共和國企業所得税法》等有關規定,海南維力自獲得高新技術企業認定當年起三年內(即2021年、2022年、2023年),將享受國家關於高新技術企業的相關優惠政策,即按15%的税率計繳企業所得税。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.